These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31904120)

  • 1. SCN2A channelopathies: Mechanisms and models.
    Hedrich UBS; Lauxmann S; Lerche H
    Epilepsia; 2019 Dec; 60 Suppl 3():S68-S76. PubMed ID: 31904120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further corroboration of distinct functional features in SCN2A variants causing intellectual disability or epileptic phenotypes.
    Begemann A; Acuña MA; Zweier M; Vincent M; Steindl K; Bachmann-Gagescu R; Hackenberg A; Abela L; Plecko B; Kroell-Seger J; Baumer A; Yamakawa K; Inoue Y; Asadollahi R; Sticht H; Zeilhofer HU; Rauch A
    Mol Med; 2019 Feb; 25(1):6. PubMed ID: 30813884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.
    Wolff M; Johannesen KM; Hedrich UBS; Masnada S; Rubboli G; Gardella E; Lesca G; Ville D; Milh M; Villard L; Afenjar A; Chantot-Bastaraud S; Mignot C; Lardennois C; Nava C; Schwarz N; Gérard M; Perrin L; Doummar D; Auvin S; Miranda MJ; Hempel M; Brilstra E; Knoers N; Verbeek N; van Kempen M; Braun KP; Mancini G; Biskup S; Hörtnagel K; Döcker M; Bast T; Loddenkemper T; Wong-Kisiel L; Baumeister FM; Fazeli W; Striano P; Dilena R; Fontana E; Zara F; Kurlemann G; Klepper J; Thoene JG; Arndt DH; Deconinck N; Schmitt-Mechelke T; Maier O; Muhle H; Wical B; Finetti C; Brückner R; Pietz J; Golla G; Jillella D; Linnet KM; Charles P; Moog U; Õiglane-Shlik E; Mantovani JF; Park K; Deprez M; Lederer D; Mary S; Scalais E; Selim L; Van Coster R; Lagae L; Nikanorova M; Hjalgrim H; Korenke GC; Trivisano M; Specchio N; Ceulemans B; Dorn T; Helbig KL; Hardies K; Stamberger H; de Jonghe P; Weckhuysen S; Lemke JR; Krägeloh-Mann I; Helbig I; Kluger G; Lerche H; Møller RS
    Brain; 2017 May; 140(5):1316-1336. PubMed ID: 28379373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond.
    Wolff M; Brunklaus A; Zuberi SM
    Epilepsia; 2019 Dec; 60 Suppl 3():S59-S67. PubMed ID: 31904126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirming an expanded spectrum of SCN2A mutations: a case series.
    Matalon D; Goldberg E; Medne L; Marsh ED
    Epileptic Disord; 2014 Mar; 16(1):13-8. PubMed ID: 24659627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phenotypic spectrum of SCN2A-related epilepsy.
    Reynolds C; King MD; Gorman KM
    Eur J Paediatr Neurol; 2020 Jan; 24():117-122. PubMed ID: 31924505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities.
    Baasch AL; Hüning I; Gilissen C; Klepper J; Veltman JA; Gillessen-Kaesbach G; Hoischen A; Lohmann K
    Epilepsia; 2014 Apr; 55(4):e25-9. PubMed ID: 24579881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic implication of a novel SCN2A mutation associated early-onset epileptic encephalopathy with Rett-like features.
    Liang JS; Lin LJ; Yang MT; Wang JS; Lu JF
    Brain Dev; 2017 Nov; 39(10):877-881. PubMed ID: 28709814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons.
    Asadollahi R; Delvendahl I; Muff R; Tan G; Rodríguez DG; Turan S; Russo M; Oneda B; Joset P; Boonsawat P; Masood R; Mocera M; Ivanovski I; Baumer A; Bachmann-Gagescu R; Schlapbach R; Rehrauer H; Steindl K; Begemann A; Reis A; Winkler J; Winner B; Müller M; Rauch A
    Hum Mol Genet; 2023 Jun; 32(13):2192-2204. PubMed ID: 37010102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperexcitability and Pharmacological Responsiveness of Cortical Neurons Derived from Human iPSCs Carrying Epilepsy-Associated Sodium Channel Nav1.2-L1342P Genetic Variant.
    Que Z; Olivero-Acosta MI; Zhang J; Eaton M; Tukker AM; Chen X; Wu J; Xie J; Xiao T; Wettschurack K; Yunis L; Shafer JM; Schaber JA; Rochet JC; Bowman AB; Yuan C; Huang Z; Hu CD; Trader DJ; Skarnes WC; Yang Y
    J Neurosci; 2021 Dec; 41(49):10194-10208. PubMed ID: 34716231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders.
    Berg AT; Thompson CH; Myers LS; Anderson E; Evans L; Kaiser AJE; Paltell K; Nili AN; DeKeyser JL; Abramova TV; Nesbitt G; Egan SM; Vanoye CG; George AL
    Brain; 2024 Aug; 147(8):2761-2774. PubMed ID: 38651838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infantile Epileptic Encephalopathy Associated With SCN2A Mutation Responsive to Oral Mexiletine.
    Foster LA; Johnson MR; MacDonald JT; Karachunski PI; Henry TR; Nascene DR; Moran BP; Raymond GV
    Pediatr Neurol; 2017 Jan; 66():108-111. PubMed ID: 27867041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cacna1g is a genetic modifier of epilepsy caused by mutation of voltage-gated sodium channel Scn2a.
    Calhoun JD; Hawkins NA; Zachwieja NJ; Kearney JA
    Epilepsia; 2016 Jun; 57(6):e103-7. PubMed ID: 27112236
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Yang XR; Ginjupalli VKM; Theriault O; Poulin H; Appendino JP; Au PYB; Chahine M
    J Neurophysiol; 2022 May; 127(5):1388-1397. PubMed ID: 35417276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic action potential clamp predicts functional separation in mild familial and severe de novo forms of
    Berecki G; Howell KB; Deerasooriya YH; Cilio MR; Oliva MK; Kaplan D; Scheffer IE; Berkovic SF; Petrou S
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5516-E5525. PubMed ID: 29844171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications.
    Johannesen KM; Liu Y; Koko M; Gjerulfsen CE; Sonnenberg L; Schubert J; Fenger CD; Eltokhi A; Rannap M; Koch NA; Lauxmann S; Krüger J; Kegele J; Canafoglia L; Franceschetti S; Mayer T; Rebstock J; Zacher P; Ruf S; Alber M; Sterbova K; Lassuthová P; Vlckova M; Lemke JR; Platzer K; Krey I; Heine C; Wieczorek D; Kroell-Seger J; Lund C; Klein KM; Au PYB; Rho JM; Ho AW; Masnada S; Veggiotti P; Giordano L; Accorsi P; Hoei-Hansen CE; Striano P; Zara F; Verhelst H; Verhoeven JS; Braakman HMH; van der Zwaag B; Harder AVE; Brilstra E; Pendziwiat M; Lebon S; Vaccarezza M; Le NM; Christensen J; Grønborg S; Scherer SW; Howe J; Fazeli W; Howell KB; Leventer R; Stutterd C; Walsh S; Gerard M; Gerard B; Matricardi S; Bonardi CM; Sartori S; Berger A; Hoffman-Zacharska D; Mastrangelo M; Darra F; Vøllo A; Motazacker MM; Lakeman P; Nizon M; Betzler C; Altuzarra C; Caume R; Roubertie A; Gélisse P; Marini C; Guerrini R; Bilan F; Tibussek D; Koch-Hogrebe M; Perry MS; Ichikawa S; Dadali E; Sharkov A; Mishina I; Abramov M; Kanivets I; Korostelev S; Kutsev S; Wain KE; Eisenhauer N; Wagner M; Savatt JM; Müller-Schlüter K; Bassan H; Borovikov A; Nassogne MC; Destrée A; Schoonjans AS; Meuwissen M; Buzatu M; Jansen A; Scalais E; Srivastava S; Tan WH; Olson HE; Loddenkemper T; Poduri A; Helbig KL; Helbig I; Fitzgerald MP; Goldberg EM; Roser T; Borggraefe I; Brünger T; May P; Lal D; Lederer D; Rubboli G; Heyne HO; Lesca G; Hedrich UBS; Benda J; Gardella E; Lerche H; Møller RS
    Brain; 2022 Sep; 145(9):2991-3009. PubMed ID: 34431999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary neurotransmitter deficiencies in epilepsy caused by voltage-gated sodium channelopathies: A potential treatment target?
    Horvath GA; Demos M; Shyr C; Matthews A; Zhang L; Race S; Stockler-Ipsiroglu S; Van Allen MI; Mancarci O; Toker L; Pavlidis P; Ross CJ; Wasserman WW; Trump N; Heales S; Pope S; Cross JH; van Karnebeek CD
    Mol Genet Metab; 2016 Jan; 117(1):42-8. PubMed ID: 26647175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional correlates of clinical phenotype and severity in recurrent SCN2A variants.
    Berecki G; Howell KB; Heighway J; Olivier N; Rodda J; Overmars I; Vlaskamp DRM; Ware TL; Ardern-Holmes S; Lesca G; Alber M; Veggiotti P; Scheffer IE; Berkovic SF; Wolff M; Petrou S
    Commun Biol; 2022 May; 5(1):515. PubMed ID: 35637276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological features: The next precise step for SCN2A developmental epileptic encephalopathy.
    Miao P; Tang S; Ye J; Wang J; Lou Y; Zhang B; Xu X; Chen X; Li Y; Feng J
    Mol Genet Genomic Med; 2020 Jul; 8(7):e1250. PubMed ID: 32400968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epilepsy-associated SCN2A (NaV1.2) variants exhibit diverse and complex functional properties.
    Thompson CH; Potet F; Abramova TV; DeKeyser JM; Ghabra NF; Vanoye CG; Millichap JJ; George AL
    J Gen Physiol; 2023 Oct; 155(10):. PubMed ID: 37578743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.